Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Apr;8(4):e70171.
doi: 10.1002/cnr2.70171.

Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis

Aneeta Channar  1 , Syed Arsalan Ahmed Naqvi  1 , Muhammad Ali Khan  1 , Arifa Bibi  1 , Akshat Saxena  1 , Nikita Tripathi  1 , Ahmad Iftikhar  2 , Ammad Raina  3 , Kaneez Zahra Rubab Khakwani  2 , Irbaz Bin Riaz  1 , Muhammad Husnain  2
Affiliations
Meta-Analysis

Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis

Aneeta Channar et al. Cancer Rep (Hoboken). 2025 Apr.

Abstract

Background: The treatment landscape for multiple myeloma continues to evolve. Recently, the addition of anti-CD38 monoclonal antibodies (mAbs) to the triplet regimen, comprising a proteasome inhibitor, an immunomodulatory agent, and a steroid, for transplant-eligible newly diagnosed multiple myeloma (TENDMM) has shown promising results.

Aims: To evaluate the overall efficacy and safety of quadruplet therapy with an anti-CD38 mAb compared to a triplet regimen.

Methods: A systematic search of Medline, Scopus, and EMBASE databases from inception to July 2024 identified relevant randomized controlled trials (RCTs). Efficacy and safety outcomes were derived using random-effects meta-analysis. Summarized outcomes include hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS), odds ratios (OR) for response rates, measurable residual disease (MRD) negativity rate, and grade 3 or higher adverse events (G ≥ 3 AEs).

Results: Five RCTs involving 2963 patients were included. A statistically significant PFS was observed for quadruplet therapy when compared to the triplet regimen (HR 0.44; 95% Confidence Interval [CI] 0.35-0.56). PFS benefit was consistent for the standard risk (SR) group (HR 0.38; 95% CI 0.27-0.52) and high risk (HiR) group (HR 0.62; 95% CI 0.41-0.92). No statistically significant benefit was observed for OS (HR 0.55; 95% CI 0.28-1.08). A statistically significant benefit was observed for the overall response rate (OR 1.77; 95% CI 1.02-3.06) and MRD negativity rate (OR 2.67; 95% CI 1.79-3.99). No significant differences were observed for G ≥ 3 AE (OR 1.21; 95% CI 0.92-1.58), lymphopenia (OR 1.09; 95% CI 0.62-1.89), and anemia (OR 1.06; 95% CI 0.83-1.37). However, a significantly increased risk was observed for all-grade thrombocytopenia (OR 1.64; 95% CI 1.37-1.97), neutropenia (OR 2.24; 95% CI 1.67-3.02) and infections (OR 1.88; 95% CI 1.07-3.31).

Conclusion: Quadruplet therapy demonstrated a favorable efficacy and safety profile, with consistent benefit across subgroups. The findings support its potential as the new standard of care for TENDMM.

Keywords: anti‐CD38 antibody; daratumumab; isatuximab; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to report.

The authors declare no conflicts of interest.

References

    1. Rajkumar S. V., Dimopoulos M. A., Palumbo A., et al., “International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma,” Lancet Oncology 15, no. 12 (2014): e538–e548, 10.1016/S1470-2045(14)70442-5. - DOI - PubMed
    1. Siegel R. L., Miller K. D., Fuchs H. E., and Jemal A., “Cancer Statistics, 2021,” CA: A Cancer Journal for Clinicians 71, no. 1 (2021): 7–33, 10.3322/caac.21654. - DOI - PubMed
    1. Kazandjian D., “Multiple Myeloma Epidemiology and Survival: A Unique Malignancy,” Seminars in Oncology 43, no. 6 (2016): 676–681, 10.1053/j.seminoncol.2016.11.004. - DOI - PMC - PubMed
    1. Kumar S. K., Lee J. H., Lahuerta J. J., et al., “Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy With IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study,” Leukemia 26, no. 1 (2012): 149–157, 10.1038/leu.2011.196. - DOI - PMC - PubMed
    1. Rajkumar S. V., “Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management,” American Journal of Hematology 97, no. 8 (2022): 1086–1107, 10.1002/ajh.26590. - DOI - PMC - PubMed

MeSH terms

Substances